



1st Asian Symposium on Precision Dosing

What Does It Take to Make Model-informed Individual Dosing the Common Practice?

December 15, 2017 ♦ Busan, Korea

Program at a Glance

9:00–10:00	Registration
10:00–10:15	Welcome & Opening Remarks
10:15–12:00	Session 1: Genetics vs Non-genetics Sources of Variability
12:00–13:00	Luncheon
13:00–14:45	Session 2: The Role of Modeling & Decision Support Tools
14:45–15:00	Coffee/Tea Break
15:00–16:45	Session 3: Facilitators & Barriers to Implementation
16:45–17:00	Closing Remarks

SYMPOSIUM VENUE

Paradise Hotel
 296, Haeundaehaebyeon-ro
 Haeundae-gu
 Busan, Korea

+82 51 749 2111~3

Sponsored by Inje University and Certara

Supported by
 PGRC, KSCPT, KoNECT, KoNSERT,
 KHIDI and University of Manchester



Program Details

Welcome Address to 1st Asian Symposium on Precision Dosing

Jae-Gook Shin

Opening Remarks by Co-Chair on Precision Dosing

Amin Rostami

Why Has Model-informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons

Session 1: Genetics vs Non-Genetics Sources of Variability

Stratified vs Individualized Dosing: Past, Present and a Future

Amin Rostami, University of Manchester & Certara, UK

Rapid Determination of Genotypes at the Point of Care: Why and How?

Toshihisa Ishikawa, NGO Personalized Medicine & Healthcare, Japan

Barriers and Solutions of Incorporating Genotype Information into Drug Labeling and Clinical Practice

Jae-Gook Shin, Inje University College of Medicine, Korea

Session 2: The Role of Modeling & Decision Support Tools

Model Qualification and Regulatory Approval:

Glass Box vs Black Box

Masoud Jamei, Certara, UK,

Case Example on Development of a Korean Virtual Population for PBPK Modeling

Howard Lee, Seoul National University Hospital and College of Medicine, Korea

Technological Advances Revolutionizing Capture of Individual Information and ICT-enabled Precision Healthcare

JoonYun Kim, SK Telecom, Korea

Session 3: Facilitators & Barriers to Implementation

Necessity & Need as Drivers for Invention: Clinical Implementation of Individualized Antipsychotic Treatment Guided by PBPK Modeling

Tom Polasek, Flinders University, Australia

Modeling and Validating Chronic Pharmacological Manipulation of Circadian Rhythms: Why and How?

Jae Kyoung Kim, KAIST, Korea

An Industrial Perspective on Model-informed Precision Dosing: Facilitators vs Barriers

Holly Kimko, Janssen Research & Development of Johnson & Johnson, US

Model-informed Personalized Dosing of Anti-tuberculosis Drugs

Jae-Gook Shin, Inje University College of Medicine, Korea

Learning from the Past and a Roadmap for the Future

Amin Rostami, University of Manchester & Certara, UK

Concluding Address for 1st Asian Symposium on Precision Dosing

Amin Rostami

Closing Remarks by Co-Chair on the Long Road Ahead for Precision Dosing

Jae-Gook Shin

About Certara

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara's solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

For more information visit www.certara.com or email sales@certara.com.